OB/GYN Clinical Alert – January 1, 2003
January 1, 2003
View Issues
-
The WAVE Trial — More of the Same
The Womens Angiographic Vitamin and Estrogen (WAVE) Trial was a randomized, controlled secondary prevention study. This study enrolled 423 postmenopausal women with coronary atherosclerosis already established at baseline by angiography. -
Cyclin E and Survival in Patients with Breast Cancer
Synopsis: The hazard ratio for death from breast cancer for patients with high total cyclin E levels as compared with those with low total cyclin E levels was 13.3 to about 8 times as high as the hazard ratios associated with other independent clinical and pathological risk factors, including axillary node status. -
Outcomes of Endometrial Cancer Patients Undergoing Surgery With Gynecologic Oncology Involvement
Synopsis: Involvement of a gynecologic oncologist at the time of primary surgery for endometrial cancer was associated with comparable outcomes in both the university and community hospital setting. -
Alcohol and Hormone Therapy Increase the Risk of Breast Cancer
Synopsis: The Nurses Health Study reports an increased incidence of breast cancer with daily alcohol consumption, hormone therapy, and an additive effect with greater drinking. -
Luteal Phase Sertraline and PMDD
Synopsis: Sertraline was significantly more effective than placebo when taken during the luteal phase for PMDD. -
Maternal Diabetes and Infant Malformations
Synopsis: Women with pregestational diabetes or gestational diabetes plus fasting hyperglycemia have a 3- to 4-fold increased risk of infant malformations, whereas women with mild gestational diabetes have malformation rates no different than the general nondiabetic obstetric population. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch: FDA Approves Claritin For OTC Use For Seasonal Rhinitis
After years of legal wrangling, the FDA has approved loratadine (Claritin, Schering-Plough) as an over-the-counter (OTC) product for the treatment of seasonal rhinitis.